November 28, 2018

Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization To Accelerate Precision Medicine Through Globally Proven Experience

PORTLAND, OR and CAMBRIDGE, MA – November 28, 2018 – Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), a Japanese in vitro diagnostics company, and MolecularMD Corporation (HQ: Portland, Oregon, United States; President and CEO: Dan Snyder), a molecular diagnostics company, announced today a master collaboration agreement targeting the challenges in current and future companion diagnostics (CDx)* development and commercialization needed to accelerate precision medicine.

The non-exclusive collaboration agreement aims to build an effective and flexible cooperation structure that will enable the companies to combine their complementary capabilities and competencies in providing experienced best-in-class and tailored solutions to pharmaceutical customers across the world for CDx development and commercialization.

The CDx market space is evolving rapidly. As the healthcare system continues to see the benefits in reducing costs and improving patient outcomes, CDx tests will further contribute to everyday outcomes. This partnership addresses the challenges brought by this evolution to increase development speed, provide flexible structures for diagnostic test alignment with therapeutic drug approval and leverage US PMA, European CE, Japanese PMDA and APAC regulatory experience in accelerating CDx and therapeutic drug commercialization. This ultimately allows patients to have unparalleled global access to the CDx test and drug combination.

Going forward, there is a possibility for the expansion of this collaboration with additional parties that can share the objectives of the relationship and ensure best solutions to customers.